PCI Biotech Holding ASA (PCIB.OL)
- GlobeNewswire
Disclosure of voting rights for Chair of the Board
Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr.
- GlobeNewswire
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website www.pcibiotech.com. For further information, please contact:Ronny Skuggedal, CEO/CFO, E-mail: rs@pcibiotech.noOffice: +47 67 11 54 00
- GlobeNewswire
PCI Biotech second half 2023 interim results
Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review OperationsThe use of fimaNAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing. The most recently reported 2023 milestone was i
